 "Govt tenders may opt for local medical devices")
Multinational medical device lobby AdvaMed has asked the United States Trade Representative (USTR) to do away with import duty benefits given to Indian companies. This demand comes as a response to India’s move to cap prices of cardiac stents and then orthopaedic knee implants, mostly dominated by multinational companies (MNCs). The National Pharmaceutical Pricing Authority (NPPA) slashed the price of coronary stent by 80 per cent and orthopaedic knee implants by 50 per cent.
Reacting to AdvaMed’s demand, the Indian manufacturers’ lobby raised its concern. Such a step would make it more difficult for Indian manufacturers to do business in
